NCT05203965View on ClinicalTrials.gov

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Familial Alcoholism Vulnerability
Interventions
DRUG

Mavoglurant (AFQ056)

Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.

DRUG

Placebo

Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.

Trial Locations (1)

06106

RECRUITING

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER